In vitro release of mitomycin C from collagen implants

Area of Science:

• Biomaterials Science
• Pharmacokinetics
• Drug Delivery Systems

Background:

• Mitomycin C (MMC) is an important chemotherapeutic agent.
• Collagen implants (CI) are utilized in various medical applications.
• Understanding the in vitro release kinetics of drugs from CI is crucial for optimizing therapeutic outcomes.

Purpose of the Study:

• To investigate the in vitro pharmacokinetics of Mitomycin C (MMC) loaded into collagen implants (CI).
• To quantify MMC absorption and release from CI under simulated physiological conditions.
• To evaluate the dissolution kinetics and half-life of MMC released from CI.

Main Methods:

• Collagen implants (CI) were incubated in varying concentrations of Mitomycin C (MMC) solutions.
• MMC-loaded CI were subjected to simulated aqueous flow.
• MMC concentrations in released samples were quantified using high-performance liquid chromatography (HPLC).
• Dissolution kinetics were analyzed using a first-order process model.

Main Results:

• A linear correlation was observed between MMC loading concentration and the total dose released from CI.
• The mean total dose delivered by CI ranged from 0.0493 to 5.291 μg, depending on initial loading.
• MMC dissolution from CI exhibited fast kinetics, with half-lives ranging from 8.8 to 10.5 minutes.

Conclusions:

• Commercially available collagen implants (CI) can be effectively loaded with Mitomycin C (MMC).
• CI demonstrate potential for providing a relatively slower release of MMC compared to traditional sponge delivery methods.
• Further clinical studies are warranted to explore the therapeutic implications of MMC-loaded CI.